Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller–Hinton Agar
The Journal of Applied Laboratory Medicine · 04.05.2023 · 8 (3) · 523-534
DOI: 10.1093/jalm/jfac131 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Applied Laboratory Medicine, online erschienen am 04.02.2023. Verfasst von Robert F Potter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Cefiderocol is a new antibiotic used to treat infections with antibiotic resistant Gram-negative bacilli. The impact of differences between Mueller–Hinton agar (MHA) brands on susceptibility testing is underexplored. Compounding the implementation of cefiderocol susceptibility testing is a lack of harmonization between different regulatory body breakpoint criteria.
Methods
We performed Kirby–Bauer disk diffusion using BD, Hardy, and Remel MHA, in addition to broth microdilution for Acinetobacter baumannii (n = 25), Enterobacterales (n = 25), Stenotrophomonas maltophilia (n = 24), and Pseudomonas aeruginosa (n = 23). We analyzed disk diffusion diameters and minimum inhibitory concentrations using interpretive criteria from the Clinical and Laboratory Standards Institute (CLSI), US Food and Drug Administration (FDA), and the European Committee on Antimicrobial Susceptibility Testing (EUCAST).
Results
Breakpoint criteria impacted interpretation of susceptibly testing results, for example with the broth microdilution we found 8% (2/25) of A. baumannii isolates change interpretation between CLSI and EUCAST and 32% (8/25) change between CLSI and FDA, 12% (3/25) of Enterobacterales change between CLSI and EUCAST, 13% (3/23) of P. aeruginosa interpretations change between CLSI and FDA, and 4% (1/25) S. maltophilia change between CLSI and FDA. There was a significant difference between the zone disk diffusion diameters for P. aeruginosa and S. maltophilia between Hardy and BD; which changed interpretation (using CLSI criteria) for 8.7% (2/23) for P. aeruginosa but 0% (0/24) for S. maltophilia.
Conclusions
Breakpoint criteria impact cefiderocol susceptibility testing interpretation for broth microdilution and disk diffusion. Choice of MHA brand can also affect result interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
ORCID-Profile: Melanie L Yarbrough
Zitieren
APA
Potter, R. F., Wallace, M. A., Muenks, C. E., Alvarado, K., Yarbrough, M. L., & Burnham, C. D. (2023). Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller–Hinton Agar. The Journal of Applied Laboratory Medicine, 8(3), 523-534. https://doi.org/10.1093/jalm/jfac131
Vancouver
Potter RF, Wallace MA, Muenks CE, Alvarado K, Yarbrough ML, Burnham CD. Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller–Hinton Agar. The Journal of Applied Laboratory Medicine. 2023;8(3):523-534. doi:10.1093/jalm/jfac131
BibTeX
@article{Potter2023,
author = {Potter, Robert F and Wallace, Meghan A and Muenks, Carol E and Alvarado, Kelly and Yarbrough, Melanie L and Burnham, Carey-Ann D},
title = {Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller–Hinton Agar},
journal = {The Journal of Applied Laboratory Medicine},
year = {2023},
volume = {8},
number = {3},
pages = {523--534},
doi = {10.1093/jalm/jfac131}
}
EUVIMED